Anika Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed orthopedic products company centered on hyaluronic-acid-based OA Pain Management and Regenerative Solutions. Its 8-K filings report operating and financial results, guidance updates, material events, clinical and regulatory disclosures for Hyalofast, and governance matters involving board and executive transitions.
Proxy materials describe shareholder voting matters, board structure, executive compensation, corporate governance practices, and the company’s focused portfolio following completed portfolio actions. The filings also identify ANIK common stock, capital-structure disclosures, risk and operating topics, and channel-based business reporting for Commercial Channel and OEM Channel activity.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award was made on June 18, 2026 at no cash cost to him and increased his direct holdings to 30,805 shares.
Each RSU represents a contingent right to receive one share of Anika Therapeutics common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with future company performance.
CONLEY SHERYL L reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Sheryl L. Conley reported an equity award of restricted stock units. She received 10,402 RSUs of common stock as a grant, with no cash paid per share. Each RSU represents the right to receive one share of common stock.
The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027. After this award, Conley directly holds 52,970 shares of Anika Therapeutics common stock, reflecting her total direct ownership reported in this filing.
Anika Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders and approvals of equity compensation plan amendments. Stockholders approved a revised omnibus incentive plan that increases the common stock reserved under the plan by 350,000 shares to 6,110,000 shares and allows all of these shares to be granted as incentive stock options. They also approved an amendment to the 2021 Employee Stock Purchase Plan, doubling its share reserve from 200,000 to 400,000 shares.
All three Class III director nominees were elected to terms ending at the 2029 annual meeting, the advisory say-on-pay vote passed, and Deloitte & Touche LLP was ratified as independent auditor for the fiscal year ending December 31, 2026. At the meeting, 11,195,667 of 13,305,624 eligible shares were represented, reflecting 84.14% of the voting power.
Anika Therapeutics, Inc. President and CEO Stephen D. Griffin reported the vesting of 12,840 restricted stock units on June 3, 2026, which converted into 12,840 shares of common stock at no cash cost as the second of three equal annual installments from a 38,520-RSU grant awarded on June 3, 2024.
To satisfy tax withholding obligations on this vesting, the issuer retained 3,769 shares at $14.41 per share. After these transactions, Griffin directly holds 45,973 shares of Anika common stock, including 739 shares acquired on May 14, 2026 under the company’s Employee Stock Purchase Plan.
Anika Therapeutics, Inc. director John B. Henneman III reported an open-market purchase of 5,000 shares of common stock at a weighted average price of $14.6639 per share. Following this transaction, he directly holds 54,871 shares. The shares were bought in multiple trades between $14.595 and $14.75.
Anika Therapeutics, Inc. reported that President and CEO Stephen D. Griffin made an open-market purchase of the company’s common stock. On April 30, 2026, he bought 12,200 shares at a weighted average price of $12.2853 per share. Following this transaction, he directly owns 36,163 shares of Anika Therapeutics common stock. The filing notes that the shares were acquired in multiple trades at prices ranging from $12.235 to $12.30 per share.
Anika Therapeutics grew its business but remained unprofitable this quarter. Revenue for the three months ended March 31, 2026 rose to $29.6 million, up 13% year over year, driven by stronger OEM sales, especially to J&J MedTech, and higher international OA pain and regenerative product revenue.
Gross margin improved to 64% from 56% as higher volume and lower inventory charges boosted profitability, yet the company posted a net loss of $5.1 million, or $0.37 per share, mainly due to increased stock-based compensation and restructuring-related severance. Adjusted EBITDA turned positive to $4.3 million from $0.1 million, reflecting stronger underlying operations.
Anika is reshaping its cost structure after divesting Arthrosurface and Parcus Medical, focusing on OA Pain Management and Regenerative Solutions. It recorded about $1.6 million of severance and $3.3 million of stock-based expense tied to a CEO transition. Cash and equivalents were $41.0 million with no debt, after funding $8.7 million of share repurchases under a $40 million program.
Anika Therapeutics Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 695,697 shares of Common Stock, representing 5.19% of the class. The filing shows sole voting power of 89,920 shares and sole dispositive power for 695,697 shares.
The filing is submitted on behalf of Vanguard Capital Management and affiliated business divisions; the signature is by Ashley Grim, Head of Global Fund Administration.
Anika Therapeutics reported first quarter 2026 revenue of $29.6 million, up 13% from $26.2 million a year earlier, driven by OEM Channel revenue of $17.0 million, up 14%, and Commercial Channel revenue of $12.6 million, up 12%.
Gross margin improved to 64.2% from 56.1% as gross profit rose to $19.0 million. Operating expenses increased to $24.5 million, including $4.9 million of one-time severance costs. The company recorded a GAAP loss from continuing operations of $5.1 million, or $0.37 per diluted share.
Non-GAAP results showed adjusted net income from continuing operations of $3.8 million, or $0.27 per diluted share, and adjusted EBITDA of $4.3 million versus $0.1 million a year earlier. Cash and cash equivalents were $41.0 million as of March 31, 2026.
The company reaffirmed its 2026 guidance, with total revenue expected between $114 million and $122.5 million and adjusted EBITDA margin between 5% and 10%. Anika also completed its previously announced $15 million 10b5-1 share repurchase at an average price of $10.76 per share. Separately, directors William Jellison and Glenn Larsen will step down at the 2026 annual meeting, and the board will be reduced from nine to seven members; their resignations are not due to any disagreement with the company.